Long post, but my thoughts after listening to the
$AMBA call and reading the docs.
Wang and Louis Gerhardy named five sectors covered by the Hanwha deal over the next 10 years.
Here's what each one actually is, in plain English, and where I think the upside sits.
1 - Physical security (security cameras)
This is the existing business. Hanwha Vision, formerly Samsung Techwin, is a top tier player in professional security cameras globally; the cameras you see in office buildings, retail stores, transport hubs, government facilities.
They've been an AMBA customer for 15 years already.
The new bit - Wang said on the call that AMBA only has a piece of Hanwha's current camera business.
Hanwha has been designing their own chips for the rest. The agreement commits Hanwha to migrating that internal silicon over to AMBA's platform.
2 - Operational automation (factory equipment)
This is Hanwha Semitech; the company that makes the machines used to assemble electronics.
The big ones place tiny components onto circuit boards at 95,000 chips per hour. What's being assembled by these machines ends up inside your phone, your EV battery management system, AI server racks.
Hanwha Semitech claims to be #1 globally in their specific equipment niche.
How AMBA fits - every one of these assembly machines uses cameras to verify each component is placed correctly. AMBA's chips can replace or upgrade the existing vision systems with smarter AI inference; catching defects faster, recalibrating in real time, predicting maintenance.
AMBA silicon could end up inside the machines that build other chips.
3 - Life sciences (biopharma)
Hanwha quietly re-entered the biopharma market in December 2023 with an $84M investment to build two manufacturing plants, one in Korea and one in the US, making tris buffer; a critical reagent used in things like DNA testing.
Korea currently imports all of its tris buffer from the US and Germany; Hanwha wants to be the domestic producer.
They also have a Bio-ENG line inside Hanwha Solutions, and they had a pharma business they sold in 2016 after a failed Merck biosimilar joint venture.
The 2023 re-entry is deliberate. They see Samsung Biologics, SK Biopharm, and others scaling aggressively and want back in.
How AMBA fits - pharma manufacturing is heavily camera driven for quality control; bottle inspection, fill line checks, particulate detection, packaging integrity, contamination monitoring.
Edge AI runs all of that locally, which is faster and safer than sending images to the cloud.
A 10 year silicon commitment is exactly what you sign when you're building facilities you'll run for 20 years.
This is the most under appreciated piece of the deal.
4 - Robotics (collaborative robot arms)
Hanwha Robotics makes "cobots" - robot arms designed to work safely next to humans.
Welding, assembly, food prep, lab work.
They launched Korea's first cobot in 2017 and spun the business out as a standalone subsidiary in 2023.
How AMBA fits - Cobots need vision to see what they're picking up, to avoid hitting people, to navigate around obstacles. This is exactly what AMBA's chips are built for.
Wang said on the call AMBA already has 15 robotics design wins with ~$100m lifetime revenue potential across the broader pipeline. Hanwha now joins that pipeline at conglomerate scale.
5 - Other industrial markets
Hanwha Group operates across chemicals, energy, shipbuilding, and aerospace.
They bought DSME (Daewoo Shipbuilding) in 2023 and rebranded it Hanwha Ocean; one of Korea's 'Big Three' shipbuilders with major naval defense contracts including submarines and warships for the Korean Navy.
Louis Gerhardy described Hanwha's broader business range on the call as including aerospace, defense, and ocean, but didn't name those as in scope today.
They're the obvious next expansion vector. The agreement framework gives AMBA a pre-built structure to extend into them if Hanwha wants to.